Latest Content

Early launch planning, streamlined patient access, and measured AI adoption help specialty therapy programs accelerate treatment and sustain success.

The PBM’s updated commercial formularies reflect negotiated pricing progress with manufacturers.

As specialty drug launches grow, pharma leaders are rethinking patient access as a core commercialization strategy to reduce delays and improve therapy starts.

In this week's Pharma Pulse, House committees advance key legislation targeting PBM kickbacks and pharmacy access, Macfarlane Packaging partners with eutecma to bring modular cold chain solutions to the UK, and more.

Intelliguard and Accucold have launched an RFID-enabled refrigerated cabinet to improve hospital medication tracking, visibility, and cold-chain control.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

The US DSCSA requires digital drug traceability to ensure patient safety, but supply chains face data errors; deploying AI adds an intelligent compliance layer to automate process tracking and protect drug access.

Pharma supply chains are embracing AI, digital twins, IoT, and DSCSA-driven traceability to improve resilience, visibility, and profitability amid rising global disruptions.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

BMS will deploy enterprise AI across functions to streamline workflows, structure field insights, and improve HCP engagement and execution.

Tommy Bramley explains how real-world evidence is reshaping how specialty pharma demonstrates value — from trial design to payer negotiations and patient outcomes.

In this week's Pharma Pulse, the Trump administration expands TrumpRx to over 600 generics, the Supreme Court clears the way for long-term Medicare drug price negotiations, Eli Lilly moves deeper into genetic medicines with a $202 million acquisition, and the FDA loses more top leadership.